# Single Source for the Continuation of the Human Pancreas Analysis Program (HPAP) for Type 1 Diabetes (HPAP-T1D) (U01 Clinical Trial Not Allowed)

Source: https://welltoldgrants.com/grants/rfa-dk-25-012-single-source-for-the-continuation-of-the-human/  
Official notice: https://www.grants.gov/search-results-detail/354719

> National Institutes of Health offered grants of up to $5.5 million to small businesses. Applications closed on October 24, 2024.

| Field | Value |
|---|---|
| Opportunity number | RFA-DK-25-012 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | October 24, 2024 |
| Award ceiling | $5.5 million |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.847 |

## Who can apply

- Small businesses

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. See full Notice of Funding Opportunity for additional details on eligibility. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

## What the grant funds

This Notice of Funding Opportunity (NOFO) is a non-competitive funding opportunity intended to fund a single award. The NIDDK is announcing its intent to issue a single source cooperative agreement to the University of Pennsylvania to continue the mission of the existing Human Pancreas Analysis Program for Type 1 Diabetes (HPAP-T1D). This NOFO will support one team of investigators with combined expertise in human pancreas physiology and pathophysiology; immunology and autoimmunity; collection, processing and multimodal analysis of human pancreatic tissues and immune compartments; and biological database building, curation and management, that will be tasked to: 1) identify, collect and intensively characterize primary pancreatic tissues and immune cells from patients with type 1 diabetes (T1D) or at risk of developing the disease, as well as age-matched controls; and 2) analyze, organize and share the data resulting from the study of these tissues through the existing PANC DB open-access resource database. HPAP-T1D is a component of the Human Islet Research Network or HIRN. HIRN was created in 2014 to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional human beta cell mass.

## Questions people ask

### Is RFA-DK-25-012 still open?

No. It closed on October 24, 2024.

### Who can apply for Single Source for the Continuation of the Human Pancreas Analysis Program (HPAP) for Type 1 Diabetes (HPAP-T1D) (U01 Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Single Source for the Continuation of the Human Pancreas Analysis Program (HPAP) for Type 1 Diabetes (HPAP-T1D) (U01 Clinical Trial Not Allowed)?

Closed October 24, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $5.5 million each.

### Who has been funded under RFA-DK-25-012?

NIH RePORTER lists 1 project funded under RFA-DK-25-012 in fiscal 2025 to 2026, at 1 institution.

### Who has won Diabetes, Digestive, and Kidney Diseases Extramural Research grants before?

The largest recipients over five fiscal years were Regents of the University of Michigan, The Trustees of the University of Pennsylvania, University of Pittsburgh - of the Commonwealth System of Higher Education. The program made 7,877 awards worth $9.6 billion in that time.